RxDoctor Payments Data

Carrie Dahl, PA

Medical · Milton, WINPI 1780845560

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Cvrx, Inc. at 44.2% of the total. Reporting peaked in 2024 at $324 and has fallen 72.6% since, to $89 in 2025.

$619in general payments, 2019–2025

Across 20 payments — averaging $30.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$273
  • Novartis$195
  • GSK$59
  • Endotronix, Inc.$35
  • Exact Sciences$22
  • Pfizer$20
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$619100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Cvrx, Inc.7$273
Novartis6$195
GSK3$59
Endotronix, Inc.1$35
Exact Sciences1$22
Pfizer1$20
Merck1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$619 in reported general payments places this provider in the 75th percentile of 247 medical providers in Wisconsin.

See all medical providers in Wisconsin

Medicare billing

Part B allowed, 2024
$25,243
Medicare patients
103
Services billed
350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide53$81,285
EliquisApixaban15$15,221
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$6,762
Levothyroxine Sodium178$2,491
ValacyclovirValacyclovir Hcl20$2,060
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$1,916
Atorvastatin Calcium207$1,731
SynthroidLevothyroxine Sodium22$1,666
Omeprazole158$1,617
Bupropion XlBupropion Hcl38$1,580
Losartan Potassium111$1,240
Duloxetine Hcl41$954
Lisinopril168$850
Potassium Chloride32$724
Gabapentin27$681

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$15,22115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 247 medical providers in Wisconsin.

Other medical in Milton

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →